After conducting checks, ThinkEquity reports that the spine market remains challenged but stable. The firm believes that NuVasive is poised to report stronger than expected Q2 results, and it maintains a Buy rating on the stock.
The market is hovering around flatline ahead of the most highly anticipated Federal Reserve meeting of the year. …